Molecular targets from VHL studies into the oxygen-sensing pathway

Current Cancer Drug Targets

Volumn 5, Issue 5, 2005, Pages 345-356

  Maynard, M A ^a   Ohh, M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

E3 ubiquitin ligase; HIF; Oxygen sensing; RCC; VHL

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 METHOXYESTRADIOL; AE 941; BEVACIZUMAB; CARBOPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; GELDANAMYCIN; GL 331; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PACLITAXEL; PROTEIN INHIBITOR; PX 12; PX 478; RAPAMYCIN; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TX 402; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; VON HIPPEL LINDAU PROTEIN;

ANAEROBIC METABOLISM; BLOOD VESSEL TONE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMPLEX FORMATION; HUMAN; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; NONHUMAN; OVARY METASTASIS; OXYGEN SENSING; PROTEIN DEGRADATION; REVIEW; UBIQUITINATION; VON HIPPEL LINDAU DISEASE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HIPPEL-LINDAU DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NUCLEAR PROTEINS; OXYGEN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 23244456759     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009054629672     Document Type: Review

References (188)

1. Maher, E. R.; Yates, J. R. W.; Harries, R.; Benjamin, C.; Harris, R.; Moore, A. T.; Ferguson-Smith, M. A. Clinical features and natural history of von Hippel-Lindau Disease. Quart. J. Med. 1990, 77, 1151-1163.
2. Iliopoulos, O.; Kaelin, W. G. von Hippel-Lindau Disease. In Hereditary Cancer, Fisher, D. E., Ed.; Humana Press: Totowa, NJ, 2000.
3. Maher, E.; Kaelin, W. G. von Hippel-Lindau Disease. Medicine 1997, 76, 381-391.
4. Gnarra, J. R.; Tory, K.; Weng, Y.; Schmidt, L.; Wei, M. H.; Li, H.; Latif, F.; Liu, S.; Chen, F.; Duh, F. -M.; Lubensky, I.; Duan, D. R.; Florence, C.; Pozzatti, R.; Walther, M. M.; Bander, N. H.; Grossman, H. B.; Brauch, H.; Pomer, S.; Brooks, J. D.; Isaacs, W. B.; Lerman, M. I.; Zbar, B.; Linehan, W. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 1994, 7, 85-90.
5. Herman, J. G.; Latif, F.; Weng, Y.; Lerman, M. I.; Zbar, B.; Liu, S.; Samid, D.; Duan, D.-S. R.; Gnarra, J. R.; Linhean, W. M.; Baylin, S. B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 1994, 91, 9700-9704.
6. Ivan, M.; Kaelin, W. G. The von Hippel-Lindau Tumor Suppressor Protein. Curr. Opin. Genes Dev. 2001, 11, 27-34.
7. Kondo, K.; Kaelin, W. G. Jr. The von Hippel-Lindau tumor suppressor gene. Exp. Cell Res. 2001, 264, 117-125.
8. Stolle, C.; Glenn, G.; Zbar, B.; Humphrey, J.; Choyke, P.; Walther, M.; Pack, S.; Hurley, K.; Andrey, C.; Klausner, R.; Linehan, W. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mut. 1998, 12, 417-423.
9. Ohh, M.; Kaelin, W. G. J. The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol. Med. Today 1999, 5, 257-263.
10. Leung, S. K.; Ohh, M. Playing tag with HIF: The VHL story. J. Biomed. Biotechnol. 2002, 2, 131-135.
11. Stebbins, C. E.; Kaelin, W. G.; Pavletich, N. P. Structure of the VHL-ElonginC-elonginB complex: implications for VHL tumor suppressor function. Science 1999, 284, 455-461.
12. Pause, A.; Lee, S.; Worrell, R. A.; Chen, D. Y. T.; Burgess, W. H.; Linehan, W. M.; Klausner, R. D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 1997, 94, 2156-2161.
13. Kibel, A.; Iliopoulos, O.; DeCaprio, J. D.; Kaelin, W. G. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995, 269, 1444-1446.
14. Duan, D. R.; Pause, A.; Burgress, W.; Aso, T.; Chen, D. Y. T.; Garrett, K. P.; Conaway, R. C.; Conaway, J. W.; Linehan, W. M.; Klausner, R. D. Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 1995, 269, 1402-1406.
15. Lonergan, K. M.; Iliopoulos, O.; Ohh, M.; Kamura, T.; Conaway, R. C.; Conaway, J. W.; Kaelin, W. G. Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Protein Requires Binding to Complexes containing Elongins B/C and Cul2. Mol. Cell. Biol. 1998, 18, 732-741.
16. Deshaies, R. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 1999, 15, 435-467.
17. Ciechanover, A.; Orian, A.; Schwartz, A. L. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000, 22, 442-451.
18. Pause, A.; Peterson, B.; Schaffar, G.; Stearman, R.; Klausner, R. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc. Natl. Acad. Sci. USA 1999, 96, 9533-9538.
19. Kamura, T.; Koepp, D. M.; Conrad, M. N.; Skowyra, D.; Moreland, R. J.; Iliopoulos, O.; Lane, W. S.; Kaelin, W. G. J.; Elledge, S. J.; Conaway, R. C.; Harper, J. W.; Conaway, J. W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999, 284, 657-661.
20. Kishida, T.; Stackhouse, T. M.; Chen, F.; Lerman, M. L; Zbar, B. Cellular proteins that bind the von Hippel-Lindau Disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res. 1995, 55, 4544-4548.
21. Ohh, M.; Takagi, Y.; Aso, T.; Stebbins, C.; Pavletich, N.; Zbar, B.; Conaway, R.; Conaway, J.; Kaelin, W. J. Synthetic peptides define critical contacts between elongin C, elongin B, and the von hippel-lindau protein. J. Clin. Invest. 1999, 104, 1583-1591.
22. Ohh, M.; Park, C. W.; Ivan, M.; Hoffman, M. A.; Kim, T.-Y.; Huang, L. E.; Chau, V.; Kaelin, W. G. Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein beta domain. Nat. Cell Biol. 2000, 2, 423-427.
23. Semenza, G. L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 1999, 15, 551-578.
24. Semenza, G. Perspectives on oxygen sensing. Cell 1999, 98, 281-284.
25. Cockman, M.; Masson, N.; Mole, D.; Jaakkola, P.; Chang, G.; Clifford, S.; Maher, E.; Pugh, C.; Ratcliffe, P.; Maxwell, P. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 2000, 275, 25733-25741.
26. Tanimoto, K.; Makino, Y.; Pereira, T.; Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000, 19, 4298-4309.
27. Sutler, C.; Laughner, E.; Semenza, G. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. USA 2000, 97, 4748-4753.
28. Kallio, P.; Wilson, W.; O'Brien, S.; Makino, Y.; Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 1999, 274, 6519-6525.
29. Salceda, S.; Caro, J. Hypoxia-inducible factor 1alpha (HIF-1 alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 1997, 272, 22642-22647.
30. Huang, L. E.; Gu, J.; Schau, M.; Bunn, H. F. Regulation of hypoxia-inducible factor !alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 1998, 95, 7987-7992.
31. Srinivas, V.; Zhang, L.; Zhu, X.; Caro, J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem. Biophys. Res. Commun. 1999, 260, 557-561.
32. O'Rourke, J.; Tian, Y. M.; Ratcliffe, P. J.; Pugh, C. W. Oxygen-regulated and transactivation domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1a. J. Biol. Chem. 1999, 274, 2060-2071.
33. Epstein, A. C.; Gleadle, J. M.; McNeill, L. A.; Hewitson, K. S.; O'Rourke, J.; Mole, D. R.; Mukherji, M.; Metzen, E.; Wilson, M. I.; Dhanda, A.; Tian, Y. M.; Masson, N,; Hamilton, D. L.; Jaakkola, P.; Barstead, R.; Hodgkin, J.; Maxwell, P. H.; Pugh, C. W.; Schofield, C. J.; Ratcliffe, P. J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107, 43-54.
34. Bruick, R. K.; McKnight, S. L. A conserved family of prolyl-4- hydroxylases that modify HIF. Science 2001, 294, 1337-1340.
35. Maynard, M. A.; Qi, H.; Chung, J.; Lee, E. H.; Kondo, Y.; Hara, S.; Conaway, R. C.; Conaway, J. W.; Ohh, M. Multiple splice variants of the human HIF-3alpha locus are targets of the VHL E3 ubiquitin ligase complex. J. Biol. Chem. 2003, 278, 11032-11040.
36. 2 sensing. Science 2001, 292, 464-468.
37. Jaakkola, P.; Mole, D. R.; Tian, Y. M.; Wilson, M. I.; Gielbert, J.; Gaskell, S. J.; Kriegsheim, A.; Hebestreit, H. F.; Mukherji, M.; Schofield, C. J.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292, 468-472.
38. Massen, N.; Willam, C.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001, 20, 5197-5206.
39. Turner, K. J.; Moore, J. W.; Jones, A.; Taylor, C. F.; Cuthbert-Heavens, D.; Han, C.; Leek, R. D.; Gatter, K. C.; Maxwell, P. H.; Ratcliffe, P. J.; Cranston, D.; Harris, A. L. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002, 62, 2957-2961.
40. Koukourakis, M. I.; Giatromanolaki, A.; Skarlatos, J.; Corti, L.; Blandamura, S.; Piazza, M.; Gatter, K. C.; Harris, A. L. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001, 61, 1830-1832.
41. Zhong, H.; De Marzo, A. M.; Laughner, E.; Lim, M.; Hilton, D. A.; Zagzag, D.; Buechler, P.; Isaacs, W. B.; Semenza, G. L.; Simons, J. W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59, 5830-5835.
42. Talks, K. L.; Turley, H.; Gatter, K. C.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 2000, 157, 411-421.
43. Schindl, M.; Schoppmann, S. F.; Samonigg, H.; Hausmaninger, H.; Kwasny, W.; Gnant, M.; Jakesz, R.; Kubista, E.; Birner, P.; Oberhuber, G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 2002, 8, 1831-1837.
44. Birner, P.; Schindl, M.; Obermair, A.; Breitenecker, G.; Oberhuber, G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 2001, 7, 1661-1668.
45. Burri, P.; Djonov, V.; Aebersold, D. M.; Lindel, K.; Studer, U.; Altermatt, H. J.; Mazzucchelli, L.; Greiner, R. H.; Gruber, G. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56, 494-501.
46. Birner, P.; Schindl, M.; Obermair, A.; Plank, C.; Breitenecker, G.; Oberhuber, G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000, 60, 4693-4696.
47. Bos, R.; van der Groep, P.; Greijer, A. E.; Shvarts, A.; Meijer, S.; Pinedo, H. M.; Semenza, G. L.; van Diest, P. J.; van der Wall, E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97, 1573-1581.
48. Birner, P.; Gatterbauer, B.; Oberhuber, G.; Schindl, M.; Rossler, K.; Prodinger, A.; Budka, H.; Hainfellner, J. A. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001, 92, 165-171.
49. Sivridis, E.; Giatromanolaki, A.; Gatter, K. C.; Harris, A. L.; Koukourakis, M. I. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002, 95, 1055-1063.
50. Takahashi, R.; Tanaka, S.; Hiyama, T.; Ho, M.; Kitadai, Y.; Sumii, M.; Haruma, K.; Chayama, K. Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep. 2003, 10, 797-802.
51. Laughner, E.; Taghavi, P.; Chiles, K.; Mahon, P. C.; Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 2001, 21, 3995-4004.
52. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M. M.; Simons, J. W.; Semenza, G. L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60, 1541-1545.
53. Zundel, W.; Schindler, C.; Haas-Kogan, D.; Koong, A.; Kaper, F.; Chen, E.; Gottschalk, A.; Ryan, H.; Johnson, R.; Jefferson, A.; Stokoe, D.; Giaccia, A. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000, 14, 391-396.
54. Brugarolas, J. B.; Vazquez, F.; Reddy, A.; Sellers, W. R.; Kaelin, W. G. Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003, 4, 147-158.
55. Chen, C.; Pore, N.; Behrooz, A.; Ismail-Beigi, F.; Maity, A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001, 276, 9519-9525.
56. Sang, N.; Stiehl, D. P.; Bohensky, J.; Leshchinsky, I.; Srinivas, V.; Caro, J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J. Biol. Chem. 2003, 278, 14013-14019.
57. Richard, D. E.; Berra, E.; Gothic, E.; Roux, D.; Pouyssegur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 1999, 274, 32631-32637.
58. Fukuda, R.; Hirota, K.; Fan, F.; Jung, Y. D.; Ellis, L. M.; Semenza, G. L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 2002, 277, 38205-38211.
59. Jiang, B. H.; Agani, F.; Passaniti, A.; Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997, 57, 5328-5335.
60. Selak, M. A.; Armour, S. M.; MacKenzie, E. D.; Boulahbel, H.; Watson, D. G.; Mansfield, K. D.; Pan, Y.; Simon, M. C.; Thompson, C. B.; Gottlieb, E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7, 77-85.
61. Sun, X.; Kanwar, J. R.; Leung, E.; Lehnert, K.; Wang, D.; Krissansen, G. W. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 2001, 8, 638-645.
62. Chen, J.; Zhao, S.; Nakada, K.; Kuge, Y.; Tamaki, N.; Okada, F.; Wang, J.; Shindo, M.; Higashino, F.; Takeda, K.; Asaka, M.; Katoh, H.; Sugiyama, T.; Hosokawa, M.; Kobayashi, M. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am. J. Pathol. 2003, 162, 1283-1291.
63. Ema, M.; Hirota, K.; Mimura, J.; Abe, H.; Yodoi, J.; Sogawa, K.; Poellinger, L.; Fukii-Kuriyama, Y. Molecular mechanisms of transcription activation by HLF and HIF1a in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 1999, 18, 1905-1914.
64. Pugh, C.; O'Rourke, J.; Nagao, M.; Gleadle, J.; Ratcliffe, P. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J. Biol. Chem. 1997, 272, 11205-11214.
65. Kallio, P. J.; Okamoto, K.; O'Brien, S.; Carrero, P.; Makino, Y.; Tanaka, H.; Poellinger, L. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 1998, 17, 6573-6586.
66. Carrero, P.; Okamoto, K.; Coumailleau, P.; O'Brien, S.; Tanaka, H.; Poellinger, L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 2000, 20, 402-415.
67. Arany, Z.; Huang, L. E.; Eckner, R.; Bhattacharya, S.; Jiang, C.; Goldberg, M. A.; Bunn, H. F.; Livingston, D. M. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 1996, 93, 12969-12973.
68. Kung, A. L.; Wang, S.; Klco, J. M.; Kaelin, W. G.; Livingston, D. M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 2000, 6, 1335-1340.
69. Semenza, G. L. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr. Res. 2001, 49, 614-7.
70. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 1992, 3, 65-71.
71. Carmeliet, P.; Dor, Y.; Herbert, J. M.; Fukumura, D.; Brusselmans, K.; Dewerchin, M.; Neeman, M.; Bono, F.; Abramovitch, R.; Maxwell, P.; Koch, C. J.; Ratcliffe, P.; Moons, L.; Jain, R. K.; Collen, D.; Keshert, E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394, 485-490.
72. Iyer, N. V.; Kotch, L. E.; Agani, F.; Leung, S. W.; Laughner, E.; Wenger, R. H.; Gassmann, M.; Gearhart, J. D.; Lawler, A. M.; Yu, A. Y.; Semenza, G. L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12, 149-162.
73. Ryan, H. E.; Lo, J.; Johnson, R. S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998, 17, 3005-3015.
74. Grosfeld, A.; Andre, J.; Hauguel-De Mouzon, S.; Berra, E.; Pouyssegur, J.; Guerre-Millo, M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J. Biol. Chem. 2002, 277, 42953-42957.
75. Sanchez-Elsner, T.; Botella, L. M.; Velasco, B.; Langa, C.; Bernabeu, C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 2002, 277, 43799-43808.
76. Caniggia, I.; Mostachfi, H.; Winter, J.; Gassmann, M.; Lye, S. J.; Kuliszewski, M.; Post, M. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J. Clin. Invest. 2000, 105, 577-587.
77. Benjamin, L. E.; Golijanin, D.; Itin, A.; Pode, D.; Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103, 159-165.
78. Carmeliet, P.; Mackman, N.; Moons, L.; Luther, T.; Gressens, P.; Van Vlaenderen, I.; Demunck, H.; Kasper, M.; Breier, G.; Evrard, P.; Muller, M.; Risau, W.; Edgington, T.; Collen, D. Role of tissue factor in embryonic blood vessel development. Nature 1996, 383, 73-75.
79. Chang, Y. S.; di Tomaso, E.; McDonald, D. M.; Jones, R.; Jain, R. K.; Munn, L. L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. USA 2000, 97, 14608-14613.
80. Vaupel, P.; Thews, O.; Hoeckel, M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 2001, 18, 243-259.
81. Vaupel, P.; Kelleher, D. K.; Hockel, M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 2001, 28, 29-35.
82. Bodi, I.; Bishopric, N. H.; Discher, D. J.; Wu, X.; Webster, K. A. Cell-specificity and signaling pathway of endothelin-1 gene regulation by hypoxia. Cardiovasc. Res. 1995, 30, 975-984.
83. Eckhart, A. D.; Yang, N.; Xin, X.; Faber, J. E. Characterization of the alpha1B-adrenergic receptor gene promoter region and hypoxia regulatory elements in vascular smooth muscle. Proc. Natl. Acad. Sci. USA 1997, 94, 9487-9492.
84. Hu, J.; Discher, D. J.; Bishopric, N. H.; Webster, K. A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem. Biophys, Res. Commun. 1998, 245, 894-899.
85. Lee, P. J.; Jiang, B. H.; Chin, B. Y.; Iyer, N. V.; Alam, J.; Semenza, G. L.; Choi, A. M. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J. Biol. Chem. 1997, 272, 5375-5381.
86. Melillo, G.; Musso, T.; Sica, A.; Taylor, L. S.; Cox, G. W.; Varesio, L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 1995, 182, 1683-1693.
87. Palmer, L. A.; Semenza, G. L.; Stoler, M. H.; Johns, R. A. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am. J. Physiol. 1998, 274, L212-L219.
88. Akakura, N.; Kobayashi, M.; Horiuchi, I.; Suzuki, A.; Wang, J.; Chen, J.; Niizeki, H.; Kawamura, K.; Hosokawa, M.; Asaka, M. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001, 61, 6548-6554.
89. Feldser, D.; Agani, F.; Iyer, N. V.; Pak, B.; Ferreira, G.; Semenza, G. L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999, 59, 3915-3918.
90. Tazuke, S. I.; Mazure, N. M.; Sugawara, J.; Carland, G.; Faessen, G. H.; Suen, L. F.; Irwin, J. C.; Powell, D. R.; Giaccia, A. J.; Giudice, L. C. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc. Natl. Acad. Sci. USA 1998, 95, 10188-10193.
91. Zhang, S. X.; Gozal, D.; Sachleben, L. R. Jr.; Rane, M.; Klein, J. B.; Gozal, E. Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. FASEB J. 2003, 17, 1709-1711.
92. Gunaratnam, L.; Morley, M.; Franovic, A.; de Paulsen, N.; Mekhail, K.; Parolin, D. A.; Nakamura, E.; Lorimer, I. A.; Lee, S. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 2003, 278, 44966-44974.
93. Pause, A.; Lee, S.; Lonergan, K. M.; Klausner, R. D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl. Acad. Sci. USA 1998, 95, 993-998.
94. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
95. Atlas, I.; Mendelsohn, J.; Baselga, J.; Fair, W. R.; Masui, H.; Kumar, R. Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res. 1992, 52, 3335-3339.
96. Knebelmann, B.; Ananth, S.; Cohen, H.; Sukhatme, V. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 1998, 58, 226-231.
97. Lager, D. J.; Slagel, D. D.; Palechek, P. L. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod. Pathol. 1994, 7, 544-548.
98. Bruick, R. K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA 2000, 97, 9082-9087.
99. Sowter, H. M.; Ratcliffe, P. J.; Watson, P.; Greenberg, A. H.; Harris, A. L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001, 61, 6669-6673.
100. Shoshani, T.; Faerman, A.; Mett, I.; Zelin, E.; Tenne, T.; Gorodin, S.; Moshel, Y.; Elbaz, S.; Budanov, A.; Chajut, A.; Kalinski, H.; Kamer, I.; Rozen, A.; Mor, O.; Keshet, E.; Leshkowitz, D.; Einat, P.; Skaliter, R.; Feinstein, E. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 2002, 22, 2283-2293.
101. Yatabe, N.; Kyo, S.; Maida, Y.; Nishi, H.; Nakamura, M.; Kanaya, T.; Tanaka, M.; Isaka, K.; Ogawa, S.; Inoue, M. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004, 23, 3708-3715.
102. Russo, C. A.; Weber, T. K.; Volpe, C. M.; Stoler, D. L.; Petrelli, N. J.; Rodriguez-Bigas, M.; Burhans, W. C.; Anderson, G. R. An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res. 1995, 55, 1122-1128.
103. Coquelle, A.; Toledo, F.; Stern, S.; Bieth, A.; Debatisse, M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell 1998, 2, 259-265.
104. Yoon, D. Y.; Buchler, P.; Saarikoski, S. T.; Hines, O. J.; Reber, H. A.; Hankinson, O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2001, 288, 882-886.
105. Graham, C. H.; Forsdike, J.; Fitzgerald, C. J.; Macdonald-Goodfellow, S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer 1999, 80, 617-623.
106. Wykoff, C. C.; Pugh, C. W.; Maxwell, P. H.; Harris, A. L.; Ratcliffe, P. J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000, 19, 6297-6305.
107. Krishnamachary, B.; Berg-Dixon, S.; Kelly, B.; Agani, F.; Feldser, D.; Ferreira, G.; Iyer, N.; LaRusch, J.; Pak, B.; Taghavi, P.; Semenza, G. L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003, 63, 1138-1143.
108. Hendrix, M. J.; Seftor, E. A.; Seftor, R. E.; Trevor, K. T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol. 1997, 150, 483-495.
109. Hendrix, M. J.; Seftor, E. A.; Chu, Y. W.; Trevor, K. T.; Seftor, R. E. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metast. Rev. 1996, 15, 507-525.
110. Ivanov, S.; Liao, S. Y.; Ivanova, A.; Danilkovitch-Miagkova, A.; Tarasova, N.; Weirich, G.; Merrill, M. J.; Proescholdt, M. A.; Oldfield, E. H.; Lee, J.; Zavada, J.; Waheed, A.; Sly, W.; Lerman, M. I.; Stanbridge, E. J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 2001, 158, 905-919.
111. Parkkila, S.; Rajaniemi, H.; Parkkila, A. K.; Kivela, J.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W. S. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. USA 2000, 97, 2220-2224.
112. Wykoff, C. C.; Beasley, N. J.; Watson, P. H.; Turner, K. J.; Pastorek, J.; Sibtain, A.; Wilson, G. D.; Turley, H.; Talks, K. L.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075-7083.
113. Aebersold, D. M.; Burri, P.; Beer, K. T.; Laissue, J.; Djonov, V.; Greiner, R. H.; Semenza, G. L. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61, 2911-2916.
114. Unruh, A.; Ressel, A.; Mohamed, H. G.; Johnson, R. S.; Nadrowitz, R.; Richter, E.; Katschinski, D. M.; Wenger, R. H. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003, 22, 3213-3220.
115. Comerford, K. M.; Wallace, T. J.; Karhausen, J.; Louis, N. A.; Montalto, M. C.; Colgan, S. P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62, 3387-3394.
116. Wartenberg, M.; Ling, F. C.; Muschen, M.; Klein, F.; Acker, H.; Gassmann, M.; Petrat, K.; Putz, V.; Hescheler, J.; Sauer, H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003, 17, 503-505.
117. Giatromanolaki, A.; Koukourakis, M. I.; Sivridis, E.; Turley, H.; Talks, K.; Pezzella, F.; Gatter, K. C.; Harris, A. L. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 2001, 85, 881-890.
118. Koukourakis, M. L; Giatromanolaki, A.; Sivridis, E.; Simopoulos, C.; Turley, H.; Talks, K.; Gatter, K. C.; Harris, A. L. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53, 1192-1202.
119. Maranchie, J. K.; Vasselli, J. R.; Riss, J.; Bonifacino, J. S.; Linehan, W. M.; Klausner, R. D. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002, 1, 247-255.
120. Kondo, K.; Klco, J.; Nakamura, E.; Lechpammer, M.; Kaelin Jr, W. G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1, 237-246.
121. Zimmer, M.; Doucette, D.; Siddiqui, N.; Iliopoulos, O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol. Cancer Res. 2004, 2, 89-95.
122. Ema, M.; Taya, S.; Yokotani, N.; Sogawa, K.; Matsuda, Y.; Fujii-Kuriyama, Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 1997, 94, 4273-4278.
123. Tian, H.; McKnight, S. L.; Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997, 11, 72-82.
124. Kappel, A.; Ronicke, V.; Damert, A.; Flamme, I.; Risau, W.; Breier, G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999, 93, 4284-4292.
125. Elvert, G.; Kappel, A.; Heidenreich, R.; Englmeier, U.; Lanz, S.; Acker, T.; Rauter, M.; Plate, K.; Sieweke, M.; Breier, G.; Flamme, I. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J. Biol. Chem. 2003, 278, 7520-7530.
126. Rapisarda, A.; Uranchimeg, B.; Scudiero, D. A.; Selby, M.; Sausville, E. A.; Shoemaker, R. H.; Melillo, G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002, 62, 4316-4324.
127. Rapisarda, A.; Uranchimeg, B.; Sordet, O.; Pommier, Y.; Shoemaker, R. H.; Melillo, G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004, 64, 1475-1482.
128. Rapisarda, A.; Zalek, J.; Hollingshead, M.; Braunschweig, T.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Hewitt, S. M.; Shoemaker, R. H.; Melillo, G. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004, 64, 6845-6848.
129. Chang, H.; Shyu, K. G.; Lee, C. C.; Tsai, S. C.; Wang, B. W.; Hsien Lee, Y.; Lin, S. GL331 inhibits HIF-lalpha expression in a lung cancer model. Biochem. Biophys. Res. Commun. 2003, 302, 95-100.
130. Liu, J. M.; Chen, L. T.; Chao, Y.; Li, A. F.; Wu, C. W.; Liu, T. S.; Shiah, H. S.; Chang, J. Y.; Chen, J. D.; Wu, H. W.; Lin, W. C.; Lan, C.; Whang-Peng, J. Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. Cancer Chemother. Pharmacol. 2002, 49, 425-428.
131. Atkins, M. B.; Hidalgo, M.; Stadler, W. M.; Logan, T. F.; Dutcher, J. P.; Hudes, G. R.; Park, Y.; Liou, S. H.; Marshall, B.; Boni, J. P.; Dukart, G.; Sherman, M. L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 2004, 22, 909-918.
132. Neshat, M. S.; Mellinghoff, I. K.; Tran, C.; Stiles, B.; Thomas, G.; Petersen, R.; Frost, P.; Gibbons, J. J.; Wu, H.; Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 2001, 98, 10314-10319.
133. Fong, T. A.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59, 99-106.
134. Itokawa, T.; Nokihara, H.; Nishioka, Y.; Sone, S.; Iwamoto, Y.; Yamada, Y.; Cherrington, J.; McMahon, G.; Shibuya, M.; Kuwano, M.; Ono, M. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol. Cancer Ther. 2002, 1, 295-302.
135. Mendel, D. B.; Laird, A. D.; Smolich, B. D.; Blake, R. A.; Liang, C; Hannah, A. L.; Shaheen, R. M.; Ellis, L. M.; Weitman, S.; Shawver, L. K.; Cherrington, J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 2000, 15, 29-41.
136. Zhong, X. S.; Zheng, J. Z.; Reed, E.; Jiang, B. H. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem. Biophys. Res. Commun. 2004, 324, 471-480.
137. Peterson, A. C.; Swiger, S.; Stadler, W. M.; Medved, M.; Karczmar, G.; Gajewski, T. F. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin. Cancer Res. 2004, 10, 4048-4054.
138. Fiedler, W.; Mesters, R.; Tinnefeld, H.; Loges, S.; Staib, P.; Duhrsen, U.; Flasshove, M.; Ottmann, O. G.; Jung, W.; Cavalli, F.; Kuse, R.; Thomalla, J.; Serve, H.; O'Farrell, A. M.; Jacobs, M.; Brega, N. M.; Scigalla, P.; Hossfeld, D. K.; Berdel, W. E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102, 2763-2767.
139. Giles, F. J.; Stopeck, A. T.; Silverman, L. R.; Lancet, J. E.; Cooper, M. A.; Hannah, A. L.; Cherrington, J. M.; O'Farrell, A. M.; Yuen, H. A.; Louie, S. G.; Hong, W.; Cortes, J. E.; Verstovsek, S.; Albitar, M.; O'Brien, S. M.; Kantarjian, H. M.; Karp, J. E. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003, 102, 795-801.
140. Madhusudan, S.; Deplanque, G.; Braybrooke, J. P.; Cattell, E.; Taylor, M.; Price, P.; Tsaloumas, M. D.; Moore, N.; Huson, S. M.; Adams, C.; Frith, P.; Scigalla, P.; Harris, A. L. Antiangiogenic therapy for von Hippel-Lindau disease. J. Am. Med. Assoc. 2004, 291, 943-944.
141. Girmens, J. F.; Erginay, A.; Massin, P.; Scigalla, P.; Gaudric, A.; Richard, S. Treatment of von Hippel-Lindau retinal hemangioblastotna by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am. J. Ophthalmol. 2003, 136, 194-196.
142. Aiello, L. P.; George, D. J.; Cahill, M. T.; Wong, J. S.; Cavallerano, J.; Hannah, A. L.; Kaelin, W. G. Jr. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002, 109, 1745-1751.
143. Minet, E.; Mottet, D.; Michel, G.; Roland, I.; Raes, M.; Remade, J.; Michiels, C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 1999, 460, 251-256.
144. Isaacs, J. S.; Jung, Y. J.; Mimnaugh, E. G.; Martinez, A.; Cuttitta, F.; Neckers, L. M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 2002, 277, 29936-29944.
145. Welsh, S. J.; Williams, R. R.; Birmingham, A.; Newman, D. J.; Kirkpatrick, D. L.; Powis, G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol. Cancer Ther. 2003, 2, 235-243.
146. Kirkpatrick, D. L.; Kuperus, M.; Dowdeswell, M.; Potier, N.; Donald, L. J.; Kunkel, M.; Berggren, M.; Angulo, M.; Powis, G. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem. Pharmacol. 1998, 55, 987-994.
147. Mabjeesh, N. J.; Escuin, D.; LaVallee, T. M.; Pribluda, V. S.; Swartz, G. M.; Johnson, M. S.; Willard, M. T.; Zhong, H.; Simons, J. W.; Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3, 363-375.
148. Pribluda, V. S.; Gubish, E. R. Jr.; Lavallee, T. M.; Treston, A.; Swartz, G. M.; Green, S. J. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastas. Rev. 2000, 19, 173-179.
149. Nagasawa, H.; Mikamo, N.; Nakajima, Y.; Matsumoto, H.; Uto, Y.; Hori, H. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway. AntiCancer Res. 2003, 23, 4427-4434.
150. Nagasawa, H.; Yamashita, M.; Mikamo, N.; Shimamura, M.; Oka, S.; Uto, Y.; Hori, H. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives. Comp. Biochem. Physiol. Mol. Integr. Physiol. 2002, 132, 33-40.
151. Welsh, S.; Williams, R.; Kirkpatrick, L.; Paine-Murrieta, G.; Powis, G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 2004, 3, 233-244.
152. Ko, F. N.; Wu, C. C.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84, 4226-4233.
153. Chun, Y. S.; Yeo, E. J.; Choi, E.; Teng, C. M.; Bae, J. M.; Kim, M. S.; Park, J. W. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. 2001, 61, 947-54.
154. Yeo, E. J.; Chun, Y. S.; Cho, Y. S.; Kim, J.; Lee, J. C.; Kim, M. S.; Park, J. W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 2003, 95, 516-525.
155. Gordon, M. S.; Margolin, K.; Talpaz, M.; Sledge, G. W. Jr.; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001, 19, 843-850.
156. Fernando, N. H.; Hurwitz, H. I. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin. Oncol. 2003, 30, 39-50.
157. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
158. Warren, R. S.; Yuan, H.; Matli, M. R.; Gillett, N. A.; Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 1995, 95, 1789-1797.
159. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
160. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Steinberg, S. M.; Chen, H. X.; Rosenberg, S. A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349, 427-434.
161. Karp, J. E.; Gojo, I.; Pili, R.; Gocke, C. D.; Greer, J.; Guo, C.; Qian, D.; Morris, L.; Tidwell, M.; Chen, H.; Zwiebel, J. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 2004, 10, 3577-3585.
162. Johnson, D. H.; Fehrenbacher, L.; Novotny, W. F.; Herbst, R. S.; Nemunaitis, J. J.; Jablons, D. M.; Langer, C. J.; DeVore, R. F., 3rd; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
163. Cobleigh, M. A.; Langmuir, V. K.; Sledge, G. W.; Miller, K. D.; Haney, L.; Novotny, W. F.; Reimann, J. D.; Vassel, A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 2003, 30, 117-124.
164. Kim, E. S.; Serur, A.; Huang, J.; Manley, C. A.; McCrudden, K. W.; Frischer, J. S.; Soffer, S. Z.; Ring, L.; New, T.; Zabski, S.; Rudge, J. S.; Holash, J.; Yancopoulos, G. D.; Kandel, J. J.; Yamashiro, D. J. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 2002, 99, 11399-11404.
165. Huang, J.; Frischer, J. S.; Serur, A.; Kadenhe, A.; Yokoi, A.; McCrudden, K. W.; New, T.; O'Toole, K.; Zabski, S.; Rudge, J. S.; Holash, J.; Yancopoulos, G. D.; Yamashiro, D. J.; Kandel, J. J. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. USA 2003, 100, 7785-7790.
166. Bold, G.; Altmann, K. H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Bruggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lasser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
167. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E. Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60, 2178-2189.
168. Morgan, B.; Thomas, A. L.; Drevs, J.; Hennig, J.; Buchert, M.; Jivan, A.; Horsfield, M. A.; Mross, K.; Ball, H. A.; Lee, L.; Mietlowski, W.; Fuxuis, S.; Unger, C.; O'Byrne, K.; Henry, A.; Cherryman, G. R.; Laurent, D.; Dugan, M.; Marme, D.; Steward, W. P. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003, 21, 3955-3964.
169. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors, determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9, 327-337.
170. O'Farrell, A. M.; Abrams, T. J.; Yuen, H. A.; Ngai, T. J.; Louie, S. G.; Yee, K. W.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101, 3597-3605.
171. O'Farrell, A. M.; Foran, J. M.; Fiedler, W.; Serve, H.; Paquette, R. L.; Cooper, M. A.; Yuen, H. A.; Louie, S. G.; Kim, H.; Nicholas, S.; Heinrich, M. C.; Berdel, W. E.; Bello, C.; Jacobs, M.; Scigalla, P.; Manning, W. C.; Kelsey, S.; Cherrington, J. M. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 2003, 9, 5465-5476.
172. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
173. Strumberg, D.; Richly, H.; Hilger, R. A.; Schleucher, N.; Korfee, S.; Tewes, M.; Faghih, M.; Brendel, E.; Voliotis, D.; Haase, C. G.; Schwartz, B.; Awada, A.; Voigtmann, R.; Scheulen, M. E.; Seeber, S. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. J. Clin. Oncol. 2005, 23, 965-972.
174. Ahmad, T.; Eisen, T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 2004, 10, 6388S-6392S.
175. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Valentine, P. J.; Curwen, J. O.; Musgrove, H. L.; Graham, G. A.; Hughes, G. D.; Thomas, A. P.; Stokes, E. S.; Curry, B.; Richmond, G. H.; Wadsworth, P. F.; Bigley, A. L.; Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62, 4645-4655.
176. Siemann, D. W.; Shi, W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 1233-1240.
177. Ciardiello, F.; Caputo, R.; Damiano, V.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B. M.; Fontanini, G.; Bianco, A. R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 2003, 9, 1546-1556.
178. Bates, D. ZD-6474. AstraZeneca. Curr. Opin. Investig. Drugs 2003, 4, 1468-1472.
179. Gingras, D.; Renaud, A.; Mousseau, N.; Beaulieu, E.; Kachra, Z.; Beliveau, R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. AntiCancer Res. 2001, 21, 145-155.
180. Beliveau, R.; Gingras, D.; Kruger, E. A.; Lamy, S.; Sirois, P.; Simard, B.; Sirois, M. G.; Tranqui, L.; Baffert, F.; Beaulieu, E.; Dimitriadou, V.; Pepin, M. C.; Courjal, F.; Ricard, I.; Poyet, P.; Falardeau, P.; Figg, W. D.; Dupont, E. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin. Cancer Res. 2002, 8, 1242-1250.
181. Boivin, D.; Gendron, S.; Beaulieu, E.; Gingras, D.; Beliveau, R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol. Cancer Ther. 2002, 1, 795-802.
182. Gingras, D.; Nyalendo, C.; Di Tomasso, G.; Annabi, B.; Beliveau, R. Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent. Biochem. Biophys. Res. Commun. 2004, 320, 205-212.
183. Gingras, D.; Labelle, D.; Nyalendo, C.; Boivin, D.; Demeule, M.; Barthomeuf, C.; Beliveau, R. The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity. Invest. New Drugs 2004, 22, 17-26.
184. Gingras, D.; Boivin, D.; Deckers, C.; Gendron, S.; Barthomeuf, C.; Beliveau, R. Neovastat-a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 2003, 14, 91-96.
185. Batist, G.; Patenaude, F.; Champagne, P.; Croteau, D.; Levinton, C.; Hariton, C.; Escudier, B.; Dupont, E. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann. Oncol. 2002, 13, 1259-1263.
186. Oosterwijk, E.; Debruyne, F. M.; Schalken, J. A. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin. Oncol. 1995, 22, 34-41.
187. Divgi, C. R.; O'Donoghue, J. A.; Welt, S.; O'Neel, J.; Finn, R.; Motzer, R. J.; Jungbluth, A.; Hoffman, E.; Ritter, G.; Larson, S. M.; Old, L. J. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J. Nucl. Med. 2004, 45, 1412-1421.
188. Brouwers, A. H.; van Eerd, J. E.; Frielink, C.; Oosterwijk, E.; Oyen, W. J.; Corstens, F. H.; Boerman, O. C. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131i, 90Y, 177Lu, or 186Re. J. Nucl. Med. 2004, 45, 327-337.